Antimicrobial compositions

Abstract

An anti-microbial composition, comprising a chelator (such as EDTA and its salts), and a transport enhancer (such as Methyl Sufonyl Methane; MSM) is provided. Together, the combination of the two substances unexpectedly and beneficially inhibits bacterial or fungal biofilms when administered to an area of microbial infection. Preferred formulations include spray, lotion, solution, gel, cream, ointment, soap, deodorant, surgical rinse, or dental rinse.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. Ser. No. 14 / 654,525 filed Jun. 20, 2015 and issued as U.S. Pat. No. 9,616,008 on Apr. 11, 2017, which is a 371 National Stage filing of international application filed under the Paris Convention Treaty (PCT) No. PCT / US2013 / 077332 filed Dec. 20, 2013 which claims priority to U.S. Provisional Patent Application Ser. No. 61 / 740,396 filed Dec. 20, 2012 and titled ANTIMICROBIAL COMPOSITIONS, the contents of which are incorporated herein in their entirety.TECHNICAL FIELD OF THE INVENTION[0002]This invention relates generally to the field of antimicrobial compositions. More particularly, it relates to antimicrobial agents and methods of eliminating biofilm and planktonic cells using these antimicrobial agents. In particular, the invention relates to antimicrobial compositions containing a transport enhancer and a chelating agent. In one exemplary embodiment, it relates to such compositions whi...

AI Technical Summary

Benefits of technology

The patent describes a personal cleansing product that contains a substance called MSM and a substance called EDTA. This product prevents a layer of bacteria from building up on the skin. This technology can be used to create better skincare products that help prevent skin infections and improve skin health.

Problems solved by technology

If the microbes reach a level of clinical infection, their presence is believed to impair healing and may be a contributing factor to wound chronicity.

Staphylococcal species such as S. epidermidis and S. aureus are responsible for the majority of nosocomial infections; treatment of these infections is often made much more challenging by the tendency of staphylococci to form biofilms.

Mounting evidence has shown that biofilms constitute a significant threat to human health.

Biofilm infections afflict tens of millions of patients in the U.S. annually and require a significant expenditure of health care dollars (Costerton et al.

Bacteria growing in biofilms exhibit increased resistance to antimicrobial agents and are nearly impossible to eradicate.

Bacterial biofilms are sources of contamination that are difficult to eliminate in a variety of industrial, environmental and clinical settings.

Bacterial biofilms are associated with many human and animal health and environmental problems.

Biofilms also contaminate surfaces such as water pipes and the like, and render also other industrial surfaces hard to disinfect.

Biofilms also play a detrimental role on many other non biological surfaces.

Biofilms also are the cause of undesirable body odor resulting from biofilms on the body surfaces.

Further biofilms are common on many engineering surfaces, and lead to material erosion, and to subpar engineering performance of these surfaces.

Although polymicrobial biofilms predominate in most situations single species biofilms can occur under certain circumstances and are an increasing problem on the surface of medical implants.

Biofilms often complicate treatment of chronic infections by protecting bacteria from the immune system, decreasing antibiotic efficacy and dispersing planktonic cells to distant sites that can promote re-infection.

Most importantly in the oral cavity failure to attach and grow as a biofilm will rapidly result in clearance.

Minor adjustments in the oral environment can affect these natural balances potentially leading to shifts in the ecology and changes in the species composition of oral microbial biofilms.

The protective bacterial biofilm interferes with the body's natural immune response as well as traditional methods of treatment.

However, the bacterial biofilm interferes with the efficacy of the white cells' ability to attack the bacteria.

Biofilm-forming bacteria also present obstacles to traditional, antibiotic treatments that act to kill dividing bacteria.

In particular, the bacteria in a biofilm-forming state may have already ceased cell division, rendering such antibiotics largely ineffective.

At these high doses, the antibiotic is more likely to kill the patient before the biofilm bacteria.

Images